Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Autores: Munier, Francis L.; Beck Popovic, Maja; Chantada, Guillermo Luis; Cobrinik, David; Kivelä, Tero T.; Lohmann, Dietmar; Maeder, Philippe; Moll, Annette C.; Montero Carcaboso, Angel; Moulin, Alexandre; Schaiquevich, Paula Susana; Bergin, Ciara; Dyson, Paul J.; Houghton, Susan; Puccinelli, Francesco; Vial, Yvan; Gaillard, Marie-Claire; Stathopoulos, Christina
Año de publicación: 2019
Idioma: inglés
Tipo de recurso: artículo
Estado: versión publicada
Descripción: Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a “state of metastatic grace” never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the “state of metastatic grace”, with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.
Fil: Munier, Francis L.. Universite de Lausanne; Suiza
Fil: Beck Popovic, Maja. Centre Hospitalier Universitaire Vaudois. Lausanne; Suiza
Fil: Chantada, Guillermo Luis. Hospital Sant Joan de Deu Barcelona; España. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cobrinik, David. Children's Hospital; Estados Unidos. University of Southern California; Estados Unidos
Fil: Kivelä, Tero T.. Helsinki University Hospital; Finlandia
Fil: Lohmann, Dietmar. University Hospital Essen; Alemania
Fil: Maeder, Philippe. Centre Hospitalier Universitaire Vaudois; Suiza
Fil: Moll, Annette C.. Vrije Universiteit Amsterdam; Países Bajos
Fil: Montero Carcaboso, Angel. Hospital Sant Joan de Deu Barcelona; España
Fil: Moulin, Alexandre. Universite de Lausanne; Suiza
Fil: Schaiquevich, Paula Susana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bergin, Ciara. Universite de Lausanne; Suiza
Fil: Dyson, Paul J.. Ecole Polytechnique Federale de Lausanne; Francia
Fil: Houghton, Susan. Universite de Lausanne; Suiza
Fil: Puccinelli, Francesco. Centre Hospitalier Universitaire Vaudois, Lausann; Suiza
Fil: Vial, Yvan. Universite de Lausanne; Suiza
Fil: Gaillard, Marie-Claire. Universite de Lausanne; Suiza
Fil: Stathopoulos, Christina. Universite de Lausanne; Suiza
Materia: COMPLICATION
INTRA-ARTERIAL CHEMOTHERAPY
INTRACAMERAL CHEMOTHERAPY
INTRAVITREAL CHEMOTHERAPY
LIQUID BIOPSY
METASTASIS
RETINOBLASTOMA
TREATMENT
Nivel de accesibilidad: acceso abierto
Condiciones de uso: https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
Institución: Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador: oai:ri.conicet.gov.ar:11336/123008

Acceder

id	CONICETDig_94ed2838a1d682bcc52c47594b5c3b79
oai_identifier_str	oai:ri.conicet.gov.ar:11336/123008
network_acronym_str	CONICETDig
repository_id_str	3498
network_name_str	CONICET Digital (CONICET)
spelling	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”Munier, Francis L.Beck Popovic, MajaChantada, Guillermo LuisCobrinik, DavidKivelä, Tero T.Lohmann, DietmarMaeder, PhilippeMoll, Annette C.Montero Carcaboso, AngelMoulin, AlexandreSchaiquevich, Paula SusanaBergin, CiaraDyson, Paul J.Houghton, SusanPuccinelli, FrancescoVial, YvanGaillard, Marie-ClaireStathopoulos, ChristinaCOMPLICATIONINTRA-ARTERIAL CHEMOTHERAPYINTRACAMERAL CHEMOTHERAPYINTRAVITREAL CHEMOTHERAPYLIQUID BIOPSYMETASTASISRETINOBLASTOMATREATMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a “state of metastatic grace” never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the “state of metastatic grace”, with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.Fil: Munier, Francis L.. Universite de Lausanne; SuizaFil: Beck Popovic, Maja. Centre Hospitalier Universitaire Vaudois. Lausanne; SuizaFil: Chantada, Guillermo Luis. Hospital Sant Joan de Deu Barcelona; España. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cobrinik, David. Children's Hospital; Estados Unidos. University of Southern California; Estados UnidosFil: Kivelä, Tero T.. Helsinki University Hospital; FinlandiaFil: Lohmann, Dietmar. University Hospital Essen; AlemaniaFil: Maeder, Philippe. Centre Hospitalier Universitaire Vaudois; SuizaFil: Moll, Annette C.. Vrije Universiteit Amsterdam; Países BajosFil: Montero Carcaboso, Angel. Hospital Sant Joan de Deu Barcelona; EspañaFil: Moulin, Alexandre. Universite de Lausanne; SuizaFil: Schaiquevich, Paula Susana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bergin, Ciara. Universite de Lausanne; SuizaFil: Dyson, Paul J.. Ecole Polytechnique Federale de Lausanne; FranciaFil: Houghton, Susan. Universite de Lausanne; SuizaFil: Puccinelli, Francesco. Centre Hospitalier Universitaire Vaudois, Lausann; SuizaFil: Vial, Yvan. Universite de Lausanne; SuizaFil: Gaillard, Marie-Claire. Universite de Lausanne; SuizaFil: Stathopoulos, Christina. Universite de Lausanne; SuizaPergamon-Elsevier Science Ltd2019-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/123008Munier, Francis L.; Beck Popovic, Maja; Chantada, Guillermo Luis; Cobrinik, David; Kivelä, Tero T.; et al.; Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”; Pergamon-Elsevier Science Ltd; Progress In Retinal And Eye Research; 73; 11-2019; 1-671350-9462CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S1350946218300739info:eu-repo/semantics/altIdentifier/doi/10.1016/j.preteyeres.2019.05.005info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:41:10Zoai:ri.conicet.gov.ar:11336/123008instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:41:10.955CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
title	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
spellingShingle	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity” Munier, Francis L. COMPLICATION INTRA-ARTERIAL CHEMOTHERAPY INTRACAMERAL CHEMOTHERAPY INTRAVITREAL CHEMOTHERAPY LIQUID BIOPSY METASTASIS RETINOBLASTOMA TREATMENT
title_short	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
title_full	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
title_fullStr	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
title_full_unstemmed	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
title_sort	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
dc.creator.none.fl_str_mv	Munier, Francis L. Beck Popovic, Maja Chantada, Guillermo Luis Cobrinik, David Kivelä, Tero T. Lohmann, Dietmar Maeder, Philippe Moll, Annette C. Montero Carcaboso, Angel Moulin, Alexandre Schaiquevich, Paula Susana Bergin, Ciara Dyson, Paul J. Houghton, Susan Puccinelli, Francesco Vial, Yvan Gaillard, Marie-Claire Stathopoulos, Christina
author	Munier, Francis L.
author_facet	Munier, Francis L. Beck Popovic, Maja Chantada, Guillermo Luis Cobrinik, David Kivelä, Tero T. Lohmann, Dietmar Maeder, Philippe Moll, Annette C. Montero Carcaboso, Angel Moulin, Alexandre Schaiquevich, Paula Susana Bergin, Ciara Dyson, Paul J. Houghton, Susan Puccinelli, Francesco Vial, Yvan Gaillard, Marie-Claire Stathopoulos, Christina
author_role	author
author2	Beck Popovic, Maja Chantada, Guillermo Luis Cobrinik, David Kivelä, Tero T. Lohmann, Dietmar Maeder, Philippe Moll, Annette C. Montero Carcaboso, Angel Moulin, Alexandre Schaiquevich, Paula Susana Bergin, Ciara Dyson, Paul J. Houghton, Susan Puccinelli, Francesco Vial, Yvan Gaillard, Marie-Claire Stathopoulos, Christina
author2_role	author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	COMPLICATION INTRA-ARTERIAL CHEMOTHERAPY INTRACAMERAL CHEMOTHERAPY INTRAVITREAL CHEMOTHERAPY LIQUID BIOPSY METASTASIS RETINOBLASTOMA TREATMENT
topic	COMPLICATION INTRA-ARTERIAL CHEMOTHERAPY INTRACAMERAL CHEMOTHERAPY INTRAVITREAL CHEMOTHERAPY LIQUID BIOPSY METASTASIS RETINOBLASTOMA TREATMENT
purl_subject.fl_str_mv	https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv	Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a “state of metastatic grace” never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the “state of metastatic grace”, with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality. Fil: Munier, Francis L.. Universite de Lausanne; Suiza Fil: Beck Popovic, Maja. Centre Hospitalier Universitaire Vaudois. Lausanne; Suiza Fil: Chantada, Guillermo Luis. Hospital Sant Joan de Deu Barcelona; España. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cobrinik, David. Children's Hospital; Estados Unidos. University of Southern California; Estados Unidos Fil: Kivelä, Tero T.. Helsinki University Hospital; Finlandia Fil: Lohmann, Dietmar. University Hospital Essen; Alemania Fil: Maeder, Philippe. Centre Hospitalier Universitaire Vaudois; Suiza Fil: Moll, Annette C.. Vrije Universiteit Amsterdam; Países Bajos Fil: Montero Carcaboso, Angel. Hospital Sant Joan de Deu Barcelona; España Fil: Moulin, Alexandre. Universite de Lausanne; Suiza Fil: Schaiquevich, Paula Susana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Bergin, Ciara. Universite de Lausanne; Suiza Fil: Dyson, Paul J.. Ecole Polytechnique Federale de Lausanne; Francia Fil: Houghton, Susan. Universite de Lausanne; Suiza Fil: Puccinelli, Francesco. Centre Hospitalier Universitaire Vaudois, Lausann; Suiza Fil: Vial, Yvan. Universite de Lausanne; Suiza Fil: Gaillard, Marie-Claire. Universite de Lausanne; Suiza Fil: Stathopoulos, Christina. Universite de Lausanne; Suiza
description	Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a “state of metastatic grace” never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the “state of metastatic grace”, with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.
publishDate	2019
dc.date.none.fl_str_mv	2019-11
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11336/123008 Munier, Francis L.; Beck Popovic, Maja; Chantada, Guillermo Luis; Cobrinik, David; Kivelä, Tero T.; et al.; Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”; Pergamon-Elsevier Science Ltd; Progress In Retinal And Eye Research; 73; 11-2019; 1-67 1350-9462 CONICET Digital CONICET
url	http://hdl.handle.net/11336/123008
identifier_str_mv	Munier, Francis L.; Beck Popovic, Maja; Chantada, Guillermo Luis; Cobrinik, David; Kivelä, Tero T.; et al.; Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”; Pergamon-Elsevier Science Ltd; Progress In Retinal And Eye Research; 73; 11-2019; 1-67 1350-9462 CONICET Digital CONICET
dc.language.none.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S1350946218300739 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.preteyeres.2019.05.005
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv	application/pdf application/pdf application/pdf
dc.publisher.none.fl_str_mv	Pergamon-Elsevier Science Ltd
publisher.none.fl_str_mv	Pergamon-Elsevier Science Ltd
dc.source.none.fl_str_mv	reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str	CONICET Digital (CONICET)
collection	CONICET Digital (CONICET)
instname_str	Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv	CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv	dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_	1846083523374481408
score	13.22299

Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”

Publicaciones similares